Hybrigenics - H117 results released, business on track

Hybrigenics has reported H117 financial results which have been restated to reflect the sale of the proteomics division. Hybrigenics continues to generate preclinical data from its inhibitors of ubiquitin-specific protease (USP) programme. Inecalcitol’s Phase II studies in acute myeloid leukaemia (AML) and chronic myeloid leukaemia (CML) will be expanded to other countries and combinations with other kinase inhibitors, respectively. Net cash at end July 2017 was €11m which we estimate provides runway into 2019. Our updated valuation is €129m or €2.75/share.